<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764851</url>
  </required_header>
  <id_info>
    <org_study_id>EBS-101-HV-101</org_study_id>
    <nct_id>NCT04764851</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates</brief_title>
  <official_title>A Phase 1, Open-Label, Fixed Sequence Drug-Drug Interaction Study to Evaluate the Effects of Repeat Doses of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emalex Biosciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nuventra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emalex Biosciences Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI)&#xD;
      study in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a screening period of up to 28 days, subjects will be admitted to the clinical&#xD;
      research unit into one of three cohorts. On the morning of Day 1, subjects in cohorts 1, 2,&#xD;
      and 3 will receive fasted doses of probe substrate(s) per assigned cohort. On Day 5, Cohort 2&#xD;
      only will receive a second fasted dose of probe substrates. Subjects in cohorts 1, 2, and 3&#xD;
      will receive the final fasted dose of probe substrate(s) on Day 13. Fasted ecopipam&#xD;
      administration will begin on Day 5 and will continue through Day 17 at ~2mg/kg for all&#xD;
      cohorts. Ecopipam doses will be tapered starting on Day 18 by 25 mg/day increments until&#xD;
      subjects are off drug, with final discharge occurring 24 hours after the ecopipam HCl dose&#xD;
      has been reduced to 25 mg (Day 21, 23, or 25).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A number of subjects withdrew consent leaving the study without adequate power to achieve its&#xD;
    primary end points.&#xD;
  </why_stopped>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Actual">May 7, 2021</completion_date>
  <primary_completion_date type="Actual">April 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of dextromethorphan (and its dextrorphan metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of dextromethorphan (and its dextrorphan metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of dabigatran in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of dabigatran in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of rosuvastatin in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of rosuvastatin in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of dextromethorphan (and its dextrorphan metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of dextromethorphan (and its dextrorphan metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of dabigatran in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of dabigatran in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of rosuvastatin in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of rosuvastatin in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of dextromethorphan (and its dextrorphan metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of dextromethorphan (and its dextrorphan metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of dabigatran in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of dabigatran in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of rosuvastatin in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of rosuvastatin in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of bupropion (and its 4-hydroxybupropion metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of bupropion (and its 4-hydroxybupropion metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of caffeine (and its metabolite paraxanthine) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of caffeine (and its metabolite paraxanthine) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax omeprazole (and its 5'-hydroxy omeprazole metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax omeprazole (and its 5'-hydroxy omeprazole metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of bupropion (and its 4-hydroxybupropion metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of bupropion (and its 4-hydroxybupropion metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of caffeine (and its metabolite paraxanthine) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of caffeine (and its metabolite paraxanthine) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of omeprazole (and its 5'-hydroxy omeprazole metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of omeprazole (and its 5'-hydroxy omeprazole metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of bupropion (and its 4-hydroxybupropion metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of bupropion (and its 4-hydroxybupropion metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of caffeine (and its metabolite paraxanthine) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of caffeine (and its metabolite paraxanthine) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of omeprazole (and its 5'-hydroxy omeprazole metabolite) in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of omeprazole (and its 5'-hydroxy omeprazole metabolite) in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for dextromethorphan in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for dextromethorphan in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for IV midazolam in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for IV midazolam in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for oral midazolam in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for oral midazolam in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for dabigatran in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for dabigatran in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for pitavastatin in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for pitavastatin in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for rosuvastatin in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for rosuvastatin in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for atorvastatin in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for atorvastatin in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for bupropion in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for bupropion in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for caffeine in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for caffeine in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for omeprazole in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for omeprazole in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for dextromethorphan in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for dextromethorphan in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for IV midazolam in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for IV midazolam in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for oral midazolam in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for oral midazolam in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for dabigatran in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for dabigatran in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for pitavastatin in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for pitavastatin in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for rosuvastatin in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for rosuvastatin in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for atorvastatin in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for atorvastatin in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for bupropion in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for bupropion in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for caffeine in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for caffeine in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for omeprazole in the presence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F for omeprazole in the absence of ecopipam</measure>
    <time_frame>Up to Day 18</time_frame>
    <description>Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total concentration of bilirubin in the presence of ecopipam</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Bilirubin sampling will occur on Day 1 and Day 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total concentration of bilirubin in the absence of ecopipam</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Bilirubin sampling will occur on Day 1 and Day 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unconjugated concentration of bilirubin in the presence of ecopipam</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Bilirubin sampling will occur on Day 1 and Day 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unconjugated concentration of bilirubin in the absence of ecopipam</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Bilirubin sampling will occur on Day 1 and Day 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as demonstrated by MOAA/S</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Safety and tolerability measures will be recorded at the indicated timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as demonstrated by C-SSRS</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Safety and tolerability measures will be recorded at the indicated timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as demonstrated by concomitant medications</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Safety and tolerability measures will be recorded at the indicated timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with dextromethorphan</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with IV midazolam</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with oral midazolam</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with dabigatran</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with pitavastatin</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with rosuvastatin</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with atorvastatin</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with bupropion</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with caffeine</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with omeprazole</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs with relatedness associated with ecopipam</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Subjects will be continually monitored for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of white blood cell (WBC) count (K/Ul)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of neutrophils, lymphocytes, monocytes, eosinophils, and basophils (10E3/uL)</measure>
    <time_frame>Blood samples will be collected for the assessment of hematology parameters.</time_frame>
    <description>Up to Day 25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of platelets (K/uL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of hematocrit (%)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of hemoglobin (g/dL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of Red blood cell (RBC) count (M/uL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of blood sodium, magnesium, urea, phosphorus, potassium, and chloride (mg/dL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of clinical chemistry parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of creatinine, calcium, glucose, and direct and total bilirubin (mg/dL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of clinical chemistry parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of albumin and total protein (g/dL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of clinical chemistry parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), and creatinine phosphokinase (CPK) (U/L)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of clinical chemistry parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of urine specific gravity</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of urine pH</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of urine glucose</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of urine protein</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of urine blood</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of urine ketones</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of urine bilirubin, urobilinogen, and nitrite</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of urine leukocytes by dipstick</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in white blood cell (WBC) count (K/Ul)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in neutrophils, lymphocytes, monocytes, eosinophils, and basophils (10E3/uL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in platelets (K/uL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in hematocrit (%)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in hemoglobin (g/dL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in Red blood cell (RBC) count (M/uL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of hematology parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in blood sodium, magnesium, urea, phosphorus, potassium, and chloride (mg/dL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of clinical chemistry parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in creatinine, calcium, glucose, and direct and total bilirubin (mg/dL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of clinical chemistry parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in albumin and total protein (g/dL)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of clinical chemistry parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), and creatinine phosphokinase (CPK) (U/L)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood samples will be collected for the assessment of clinical chemistry parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in urine specific gravity</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in urine pH</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in urine glucose</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in urine protein</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in urine blood</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in urine ketones</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in urine bilirubin, urobilinogen, and nitrite (Milligrams per deciliter)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day -1 to Day of Discharge in urine leukocytes by dipstick</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Urine samples will be collected for the assessment of urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of electrocardiogram (ECG) parameters: PR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) (Milliseconds)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Twelve-lead ECGs will be obtained with the participant in a supine position after a rest of at least 5 minutes using an automated ECG machine. PR, QRS, QT, and QTcF intervals will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose for the respective day in ECG parameters: PR, QRS, QT, and QTcF (Milliseconds)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Twelve-lead ECGs will be obtained with the participant in a supine position after a rest of at least 5 minutes using an automated ECG machine. PR, QRS, QT, and QTcF intervals will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of oral temperature (degrees Celsius)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Temperature will be assessed as part of vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose for the respective day in oral temperature (degrees Celsius)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Temperature will be assessed as part of vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of heart rate (beats/minute)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Heart rate will be assessed as part of vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose for the respective day in heart rate (beats/minute)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Heart rate will be assessed as part of vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of respiratory rate (breaths/minute)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Respiratory rate will be assessed as part of vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose for the respective day in respiratory rate (breaths/minute)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Respiratory rate will be assessed as part of vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of systolic blood pressure (SBP) and diastolic blood pressure (DBP) (mmHG)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood pressure will be assessed as part of vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose for the respective day in SBP and DBP (mmHG)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>Blood pressure will be assessed as part of vital signs.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Drug-Interactions</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days&#xD;
Cohort 1 Probe Cocktail given on 2 separate days:&#xD;
midazolam: 1 g infused IV&#xD;
caffeine: 200 mg oral tablet&#xD;
omeprazole: two 20 mg oral tablets&#xD;
dextromethorphan: 1.6mL (containing ~10 mg) oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days&#xD;
Cohort 2 Probe Cocktail given on 3 separate days:&#xD;
midazolam: 10 g/mL given as 1mL oral solution.&#xD;
dabigatran: 375 g/mL and pitavastatin: 10 g/mL given as 1mL oral solution&#xD;
rosuvastatin: 25 g/mL and atorvastatin: 50 g/mL given as 2mL oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days&#xD;
Cohort 3 Probe Cocktail given on 2 separate days:&#xD;
- bupropion: 100mg oral tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ecopipam HCl ~2mg/kg/day</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cohort 1 Probe Cocktail</intervention_name>
    <description>dextromethorphan, caffeine, omeprazole, and midazolam</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cohort 2 Probe Cocktail</intervention_name>
    <description>dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cohort 3 Probe Cocktail</intervention_name>
    <description>bupropion</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects or female subjects of non-childbearing potential&#xD;
&#xD;
          -  18 and &lt;55 years of age at the time of consent&#xD;
&#xD;
          -  BMI &gt;18.5 and &lt;30 kg/m2 and a weight of 50 kg for males or 45 kg for females&#xD;
&#xD;
          -  Sexually active males must use a double barrier method of contraception during the&#xD;
             study and for at least 90 days after the last dose of study drug&#xD;
&#xD;
          -  Male subjects must be willing not to donate sperm until 90 days following the last&#xD;
             study drug administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal or family History of significant medical illness&#xD;
&#xD;
          -  Clinically significant abnormalities on screening tests/exams&#xD;
&#xD;
          -  History of or significant risk of committing suicide&#xD;
&#xD;
          -  Donation of plasma within 7 days prior to dosing&#xD;
&#xD;
          -  Donation or significant loss of blood within 30 days prior to the first dosing&#xD;
&#xD;
          -  Major surgery within 3 months or minor surgery within 1 month prior to admission&#xD;
&#xD;
          -  Use of prohibited prescription, over-the-counter medications or natural health&#xD;
             products&#xD;
&#xD;
          -  Alcohol-based products 24 hours prior to admission&#xD;
&#xD;
          -  Female subjects who are currently pregnant or lactating&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Use of tobacco or nicotine products within 3 months prior to Screening&#xD;
&#xD;
          -  Significant alcohol consumption&#xD;
&#xD;
          -  History of drug abuse within the previous 2 years, or a positive drug screen&#xD;
&#xD;
          -  History of allergy to study medications&#xD;
&#xD;
          -  Undergoing abrupt discontinuation of alcohol or sedatives&#xD;
&#xD;
          -  Not suitable for study in the opinion of the Principal Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Syneos Health Clinical Research Services, LLC.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ecopipam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

